CoChat
Sign Up
Cited by 1,173Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.

Pharmacologic Therapy for Type 2 Diabetes Mellitus

DeFronzo, Ralph A.·1999·Annals of Internal Medicine
DOI 10.7326/0003-4819-131-4-199908170-00008
Open this paper in CoChat — free account

Abstract

Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action. An elevated rate of basal hepatic glucose production in the presence of hyperinsulinemia is the primary cause of fasting hyperglycemia; after a meal, impaired suppression of hepatic glucose production by insulin and decreased insulin-mediated glucose uptake by muscle contribute almost equally to postprandial hyperglycemia. In the United States, five classes of oral agents, each of which works through a different mechanism of action, are currently available to improve glycemic control in patients with type 2 diabetes. The recently completed United Kingdom Prospective Diabetes Study (UKPDS) has shown that type 2 diabetes mellitus is a progressive disorder that can be treated initially with oral agent monotherapy but will eventually require the addition of other oral agents, and that in many patients, insulin therapy will be needed to achieve targeted glycemic levels. In the UKPDS, improved glycemic control, irrespective of the agent used (sulfonylureas, metformin, or insulin), decreased the incidence of microvascular complications (retinopathy, neuropathy, and nephropathy). This review examines the goals of antihyperglycemic therapy and reviews the mechanism of action, efficacy, nonglycemic benefits, cost, and safety profile of each of the five approved classes of oral agents. A rationale for the use of these oral agents as monotherapy, in combination with each other, and in combination with insulin is provided.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-131-4-199908170-00008

Cites

172 of 172 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Research works printed but not linked: 27

  1. DeFronzo RA, 1997, Diabetes Rev, 5, 177
  2. 1997, Diabetes, 20, 1183
  3. Kelley DE, 1995, Diabetes Rev, 3, 366
  4. Schneider SH, 1995, Diabetes Rev, 3, 378
  5. Klimt CR, 1970, Diabetes, 19, 747
  6. Meinert CL, 1970, Diabetes, 19, 789
  7. Edelman SV, 1995, Diabetes Rev, 3, 308
  8. Rossetti L, 1995, Clin Invest Med, 18, 255
  9. Haupt E, 1977, Med Klin, 72, 1529
  10. Camerini-Davalos R, 1962, Metabolism, 11, 74
  11. Berger W, 1986, Schweiz Med Wochenschr, 116, 145
  12. Cusi K, 1996, J Clin Endocrinol Metab, 81, 4059
  13. Cusi K, 1998, Diabetes Rev, 6, 89
  14. Reaven GM, 1992, J Clin Endocrinol Metab, 74, 1020
  15. Vague P, 1994, Diabetologia, 37, 236
  16. Campbell IW, 1985, Horm Metab Res Suppl, 15, 105
  17. Lebovitz HE, 1995, Clinical Diabetes, 13, 99
  18. Fonesca VA, 1998, J Clin Endocrinol Metab, 83, 3169
  19. Berger S, 1998, Diabetes, 47, A18
  20. Cefalu WT, 1996, Diabetes, 45, 201A
  21. Haupt E, 1991, Diabete Metab, 17, 224
  22. Rodger NW, 1995, Clin Invest Med, 18, 318
  23. Bergenstal R, 1998, Diabetes, 7, A89
  24. Groop L, 1991, Diabete Metab, 17, 218
  25. Klein W, 1991, Diabete Metab, 17, 235
  26. Vigneri R, 1991, Diabete Metab, 17, 232
  27. Aviles-Santa L, 1998, Diabetes, 47, A89

Cited by

Sorted by citations

See all 1,173

Related

See all

Metadata

Authors
DeFronzo, R. A.
Affiliations
The University of Texas at San Antonio Health Science Center (US)
Corresponding author
DeFronzo, Ralph A.
ORCID
DeFronzo, Ralph A.
Venue
Annals of Internal Medicine
Publisher
American College of Physicians
Published
1999-08-17
Volume
131
Issue
4
Pages
281-303
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
DOI
10.7326/0003-4819-131-4-199908170-00008
OpenAlex
W2036939737
Cited by
1,173
References
172
Citations by year
2026: 8 · 2025: 5 · 2024: 17 · 2023: 20 · 2022: 17 · 2021: 26 · 2020: 22 · 2019: 36 · 2018: 23 · 2017: 33 · 2016: 37 · 2015: 36 · 2014: 50 · 2013: 55 · 2012: 43
FWCI
10.70
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, oral antidiabetic drugs, glycemic control, insulin therapy, metformin, sulfonylureas, insulin resistance, insulin secretion, hepatic glucose production, microvascular complications, UKPDS, drug safety and efficacy, combination therapy
MeSH terms
Troglitazone, Administration, Oral, Algorithms, Carbamates, Chromans, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin, Metformin, Piperidines, Sulfonylurea Compounds, Thiazoles, Trisaccharides, Evidence-Based Medicine, Acarbose, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review